Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA:688192)

Market Cap	28.71B
Revenue (ttm)	607.75M
Net Income (ttm)	-867.44M
Shares Out	461.19M
EPS (ttm)	-2.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,788,235
Average Volume	2,889,041
Open	63.70
Previous Close	63.14
Day's Range	61.78 - 63.70
52-Week Range	37.58 - 86.18
Beta	0.15
RSI	48.25
Earnings Date	May 8, 2026

About SHA:688192

Dizal (Jiangsu) Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of cancer and immunological diseases. Its assets include the ZEGFROVY, for the treatment of solid tumors; Golidocitinib to treat hematological malignancy, solid tumors, and immunological diseases; Birelentinib indicated for hematological malignancy; DZD2269, DZD1516, and DZD6008 for solid tumors; and GW5282 for hematological malignancy and solid tumors. The company was founded in 2017 and is based in Shan...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2017
• Employees: 852
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688192

Financial Performance

In 2024, SHA:688192's revenue was 359.90 million, an increase of 294.24% compared to the previous year's 91.29 million. Losses were -845.96 million, -23.63% less than in 2023.